培美曲塞联合卡铂与吉西他滨联合卡铂一线治疗晚期非鳞非小细胞肺癌的临床观察

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (12): 1401-1405.

培美曲塞联合卡铂与吉西他滨联合卡铂一线治疗晚期非鳞非小细胞肺癌的临床观察

陈冬云, 赵文英, 吉兆宁

皖南医学院弋矶山医院肿瘤内科,芜湖 241000,安徽

收稿日期:2013-09-26 修回日期:2013-11-26 出版日期:2013-12-26 发布日期:2014-01-04
作者简介:陈冬云,女,硕士,医师,研究方向:肿瘤的化疗及综合治疗。Tel: 13515537868 E-mail: chdy228@aliyun.com

Clinical study comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line treatment in patients with advanced nonsquamous non-small cell lung cancer

CHEN Dong-yun, ZHAO Wen-ying, JI Zhao-ning

Department of Medical Oncology,Yijishan Hospital, Wannan Medical College,Wuhu 241000,Anhui,China

Received:2013-09-26 Revised:2013-11-26 Online:2013-12-26 Published:2014-01-04

摘要/Abstract

摘要： 目的: 观察培美曲塞联合卡铂与吉西他滨联合卡铂治疗晚期非鳞非小细胞肺癌(NSCLC)的近期疗效及毒副反应。方法: 57例ⅢB-Ⅳ期经病理组织学和(或)细胞学检查确诊的晚期非鳞NSCLC患者,其中培美曲塞组(PC组)26例,吉西他滨组(GC组)31例,分别给予培美曲塞联合卡铂和吉西他滨联合卡铂方案治疗至少2周期以上,评价其近期疗效及毒副反应。结果: PC组和GC组的客观缓解率(42.3% vs 41.9%),疾病控制率(88.5% vs 80.6%),中位无进展生存期(5.9 个月vs 4.7 个月)差异均无统计学意义(P＞0.05)。两组的主要毒副反应均为骨髓抑制和胃肠道反应,PC组Ⅲ-Ⅳ度血小板减少的发生率明显低于GC组(P=0.042)。结论: 培美曲塞联合卡铂和吉西他滨联合卡铂一线治疗晚期非鳞NSCLC疗效相近,培美曲塞组不良反应轻,安全性更好。

关键词: 非小细胞肺癌, 培美曲塞, 吉西他滨, 卡铂, 化学治疗

Abstract: AIM: To observe the clinical efficacy and adverse effect of Pemetrexed combined with Carboplatin and Gemcitabine combined with Carboplatin to treat non-squamous non-small cell lung cancer.METHODS: 57 pathologically confirmed patients with ⅢB/Ⅳ staged NSCLC were recruited in this study. 26 patients treated with Pemetrexed plus Carboplatin (PC group) and 31 with Gemcitabine plus Carboplatin (GC group) more than 2 cycles.The latest clinical efficacy and adverse effect were evaluated.RESULTS: No statistical difference was observed in objective response rate(ORR) (42.3% vs 41.9%),disease control rate(88.5% vs 80.6%)and median progression free survival(PFS)(5.9 months vs 4.7 months) between the PC group and GC group. The main common adverse reactions were myelosuppression and gastrointestinal response in both groups.The rates of Ⅲ-Ⅳdegree thrombocytopenia were obviously less observed on the PC group compared with GC group.CONCLUSION: The both groups have similar clinical efficacy as the treatment of Nonsquamous NSCLC,but the Pemetrexed combined with Carboplatin has better safety and less reaction.

Key words: Non-small cell lung cancer, Pemetrexed, Gemcitabine, Carboplatin, Chemotherapy

中图分类号:

R734

陈冬云, 赵文英, 吉兆宁. 培美曲塞联合卡铂与吉西他滨联合卡铂一线治疗晚期非鳞非小细胞肺癌的临床观察[J]. 中国临床药理学与治疗学, 2013, 18(12): 1401-1405.

CHEN Dong-yun, ZHAO Wen-ying, JI Zhao-ning. Clinical study comparing pemetrexed plus carboplatin with gemcitabine plus carboplatin as first-line treatment in patients with advanced nonsquamous non-small cell lung cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(12): 1401-1405.

参考文献

[1] 张湘茹,王惠杰.肺癌[M] //孙燕,石远凯,主编,临床肿瘤内科学手册.5版.北京:人民卫生出版社,2007:414-419.
[2] 蔡利.晚期非小细胞肺癌内科治疗的优化选择[M] //秦叔逵,马军,吴一龙,主编,中国临床肿瘤学进展. 北京:人民卫生出版社,2012:72-75.
[3] Chattopadhyay S, Moran RG, Goldman ID,et al.Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications[J]. Mol Cancer Ther,2007,6(2):404-417.
[4] Jiang J, Li L, Wang X, et al. A meta-analysis of pemetrexed plus platinum chemotherapy versus gemcitabine plus platinum chemotherapy for advanced non-small cell lung cancer[J]. Zhongguo Fei Ai Za Zhi,2011,14(1):43-48.
[5] Fleeman N, Bagust A, McLeod C,et al. Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer[J]. Health Technol Assess, 2010,14 (Suppl 1):47-53.
[6] Zhang X, Lu J, Xu J, et al.Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis[J]. Respirology,2013,18(1):131-139.
[7] Treat J, Scagliotti GV, Peng G, et al. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials[J]. Lung Cancer, 2012,76(2):222-227.
[8] Hanna N, Shepherd FA, Fossella FV,et al.Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy[J]. J Clin Oncol, 2004 ,22(9):1589-1597.
[9] Weiss GJ, Langer C, Rosell R, et al. Elderly patients benefit from second-line cytotoxic chemotherapy: a subset analysis of a randomized phase III trial of pemetrexed compared with docetaxel in patients with previously treated advanced non-small-cell lung cancer[J]. J Clin Oncol, 2006,24(27):4405-4411.
[10] Scagliotti GV, Parikh P, von Pawel J,et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer[J]. J Clin Oncol, 2008,26(21):3543-3551.
[11] Zukin M, Barrios CH, Rodrigues Pereira J, et al.Randomized phase III trial of single-agent pemetrexed versus carboplatin and pemetrexed in patients with advanced non-small-cell lung cancer and Eastern Cooperative Oncology Group performance status of 2[J]. J Clin Oncol,2013,31(23):2849-2853.
[12] Scagliotti G, Brodowicz T, Shepherd FA, et al. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer[J]. J Thorac Oncol, 2011,6(1):64-70.
[13] Gridelli C, Brodowicz T, Langer CJ, et al.Pemetrexed therapy in elderly patients with good performance status: analysis of two phase III trials of patients with nonsquamous non-small-cell lung cancer[J]. Clin Lung Cancer, 2012 ,13(5):340-346.
[14] 黄岩,刘云鹏,周建英,等.培美曲塞联合顺铂对比吉西他滨联合顺铂一线治疗晚期非鳞非小细胞肺癌的随机、对照、多中心临床研究[J].中国肺癌杂志,2012,15(10):576-582.

[1]	何杨, 杨魁, 栾家杰. CDA-G208A基因多态性对吉西他滨一线治疗肺鳞癌的疗效影响[J]. 中国临床药理学与治疗学, 2023, 28(3): 299-306.
[2]	张威, 王鸿渊, 雷晓航, 赵英帅, 吕炜超, 张建国. 中高危膀胱癌应用卡介苗+吡柔比星与卡介苗+吉西他滨预防术后复发的效果及对血清AGR、PON1的影响[J]. 中国临床药理学与治疗学, 2023, 28(10): 1146-1153.
[3]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[4]	张可心, 贾文静, 崔佳文, 敖路遥, 周芳, 王广基, 刘嘉莉. 第三代EGFR酪氨酸激酶抑制剂在非小细胞肺癌临床治疗中的应用及研究进展[J]. 中国临床药理学与治疗学, 2022, 27(9): 1016-1030.
[5]	叶小弟, 缪云萍, 陈爱瑛, 程敏, 田雪君, 郑高利. 裸鼠原位非肌层浸润性膀胱癌模型的优选及验证[J]. 中国临床药理学与治疗学, 2022, 27(4): 473-480.
[6]	裴清华, 孙建立. 奥希替尼获得性耐药的研究进展[J]. 中国临床药理学与治疗学, 2021, 26(1): 105-112.
[7]	魏为添, 陈晟, 汪亮, 曾剑. 灯盏花素对非小细胞肺癌A549细胞的促凋亡作用[J]. 中国临床药理学与治疗学, 2020, 25(6): 618-624.
[8]	赵全铭，杨洋. 晚期三阴性乳腺癌的药物治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(4): 475-480.
[9]	王海莉，巩天晓，周士霞，梅家转，张中冕. 甲磺酸阿帕替尼三线治疗晚期非小细胞肺癌患者的疗效及安全性分析[J]. 中国临床药理学与治疗学, 2019, 24(5): 567-572.
[10]	杨科，李峻岭，杜斌，田中秋，景秀娟. 白蛋白结合型紫杉醇二线及以上治疗晚期非小细胞肺癌的单臂、单中心探索性临床研究[J]. 中国临床药理学与治疗学, 2019, 24(11): 1281-1286.
[11]	王海霞，刘兴安，侯继院，龚哲，单国用. KDR基因遗传变异对贝伐珠单抗一线治疗晚期非小细胞肺癌患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2018, 23(7): 802-808.
[12]	李伟文，黎媛，孙蕾，黄公才，赵中伟. 艾迪注射液对培美曲塞联合奈达铂治疗晚期非小细胞肺癌的增效作用[J]. 中国临床药理学与治疗学, 2018, 23(3): 325-328.
[13]	张艳霞，张正顺，陈绍仪，孔学礼，周佳玮. 当归挥发油联合卡铂对人肺腺癌A549细胞增殖及凋亡的影响[J]. 中国临床药理学与治疗学, 2017, 22(7): 755-761.
[14]	高中原，孙更，李敏，谌茜，李萍，王雪融. 柚皮苷通过下调p70S6K抑制非小细胞肺癌细胞生长的作用机制研究[J]. 中国临床药理学与治疗学, 2017, 22(7): 762-766.
[15]	容国义，王淑美，唐末. 中医化痰法治疗非小细胞肺癌疗效的Meta分析[J]. 中国临床药理学与治疗学, 2017, 22(7): 787-794.